KYMR PE Ratio & Valuation,Is KYMR Overvalued

KYMR Relative Valuation

KYMR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, KYMR is overvalued; if below, it's undervalued.

Historical Valuation

Kymera Therapeutics Inc (KYMR) is now in the Overvalued zone, suggesting that its current forward PS ratio of 154.08 is considered Overvalued compared with the five-year average of -16.35. The fair price of Kymera Therapeutics Inc (KYMR) is between 15.82 to 33.95 according to relative valuation methord. Compared to the current price of 89.68 USD , Kymera Therapeutics Inc is Overvalued By 164.12%.

Relative Value

Fair Zone

15.82-33.95

Current Price：89.68

164.12%

Overvalued

-24.00

-15.37

EV/EBITDA

Kymera Therapeutics Inc. (KYMR) has a current EV/EBITDA of -15.37. The 5-year average EV/EBITDA is -14.16. The thresholds are as follows: Strongly Undervalued below -45.65, Undervalued between -45.65 and -29.91, Fairly Valued between 1.58 and -29.91, Overvalued between 1.58 and 17.33, and Strongly Overvalued above 17.33. The current Forward EV/EBITDA of -15.37 falls within the Historic Trend Line -Fairly Valued range.

-16.96

EV/EBIT

Kymera Therapeutics Inc. (KYMR) has a current EV/EBIT of -16.96. The 5-year average EV/EBIT is -10.72. The thresholds are as follows: Strongly Undervalued below -32.91, Undervalued between -32.91 and -21.81, Fairly Valued between 0.38 and -21.81, Overvalued between 0.38 and 11.47, and Strongly Overvalued above 11.47. The current Forward EV/EBIT of -16.96 falls within the Historic Trend Line -Fairly Valued range.

154.08

Kymera Therapeutics Inc. (KYMR) has a current PS of 154.08. The 5-year average PS is 35.74. The thresholds are as follows: Strongly Undervalued below -3.20, Undervalued between -3.20 and 16.27, Fairly Valued between 55.21 and 16.27, Overvalued between 55.21 and 74.68, and Strongly Overvalued above 74.68. The current Forward PS of 154.08 falls within the Strongly Overvalued range.

-28.65

P/OCF

Kymera Therapeutics Inc. (KYMR) has a current P/OCF of -28.65. The 5-year average P/OCF is -27.98. The thresholds are as follows: Strongly Undervalued below -111.23, Undervalued between -111.23 and -69.61, Fairly Valued between 13.64 and -69.61, Overvalued between 13.64 and 55.26, and Strongly Overvalued above 55.26. The current Forward P/OCF of -28.65 falls within the Historic Trend Line -Fairly Valued range.

-25.89

P/FCF

Kymera Therapeutics Inc. (KYMR) has a current P/FCF of -25.89. The 5-year average P/FCF is -17.45. The thresholds are as follows: Strongly Undervalued below -46.26, Undervalued between -46.26 and -31.85, Fairly Valued between -3.04 and -31.85, Overvalued between -3.04 and 11.36, and Strongly Overvalued above 11.36. The current Forward P/FCF of -25.89 falls within the Historic Trend Line -Fairly Valued range.

Kymera Therapeutics Inc (KYMR) has a current Price-to-Book (P/B) ratio of 6.80. Compared to its 3-year average P/B ratio of 3.41 , the current P/B ratio is approximately 99.61% higher. Relative to its 5-year average P/B ratio of 4.47, the current P/B ratio is about 52.20% higher. Kymera Therapeutics Inc (KYMR) has a Forward Free Cash Flow (FCF) yield of approximately -3.21%. Compared to its 3-year average FCF yield of -9.18%, the current FCF yield is approximately -65.03% lower. Relative to its 5-year average FCF yield of -7.26% , the current FCF yield is about -55.77% lower.

6.80

P/B

Median3y

3.41

Median5y

4.47

-3.21

FCF Yield

Median3y

-9.18

Median5y

-7.26

Competitors Valuation Multiple

The average P/S ratio for KYMR's competitors is 61.60, providing a benchmark for relative valuation. Kymera Therapeutics Inc Corp (KYMR) exhibits a P/S ratio of 154.08, which is 150.14% above the industry average. Given its robust revenue growth of -26.12%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of KYMR increased by 122.92% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -1.67K to -2.97K.

The secondary factor is the P/E Change, contributed 71.05%to the performance.

Overall, the performance of KYMR in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-26.12%

3.74M → 2.76M

Revenue Growth

77.99%

-1.67K → -2.97K

Margin Expansion

71.05%

-14.57 → -24.92

P/E Change

122.92%

40.23 → 89.68

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Kymera Therapeutics Inc (KYMR) currently overvalued or undervalued?

What is Kymera Therapeutics Inc (KYMR) fair value?

KYMR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Kymera Therapeutics Inc (KYMR) is between 15.82 to 33.95 according to relative valuation methord.

How does KYMR's valuation metrics compare to the industry average?

What is the current P/B ratio for Kymera Therapeutics Inc (KYMR) as of Dec 15 2025?

As of Dec 15 2025, Kymera Therapeutics Inc (KYMR) has a P/B ratio of 6.80. This indicates that the market values KYMR at 6.80 times its book value.

What is the current FCF Yield for Kymera Therapeutics Inc (KYMR) as of Dec 15 2025?

As of Dec 15 2025, Kymera Therapeutics Inc (KYMR) has a FCF Yield of -3.21%. This means that for every dollar of Kymera Therapeutics Inc’s market capitalization, the company generates -3.21 cents in free cash flow.

What is the current Forward P/E ratio for Kymera Therapeutics Inc (KYMR) as of Dec 15 2025?

As of Dec 15 2025, Kymera Therapeutics Inc (KYMR) has a Forward P/E ratio of -24.00. This means the market is willing to pay $-24.00 for every dollar of Kymera Therapeutics Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Kymera Therapeutics Inc (KYMR) as of Dec 15 2025?

As of Dec 15 2025, Kymera Therapeutics Inc (KYMR) has a Forward P/S ratio of 154.08. This means the market is valuing KYMR at $154.08 for every dollar of expected revenue over the next 12 months.

KYMR Valuation